Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) is one of 970 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Eterna Therapeutics to related companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.
Valuation & Earnings
This table compares Eterna Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Eterna Therapeutics||$5.80 million||-$24.58 million||-0.37|
|Eterna Therapeutics Competitors||$2.01 billion||$213.01 million||-5.37|
Eterna Therapeutics’ peers have higher revenue and earnings than Eterna Therapeutics. Eterna Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
|Net Margins||Return on Equity||Return on Assets|
|Eterna Therapeutics Competitors||-2,315.73%||-325.78%||-32.96%|
Insider & Institutional Ownership
6.0% of Eterna Therapeutics shares are held by institutional investors. Comparatively, 40.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 35.4% of Eterna Therapeutics shares are held by insiders. Comparatively, 15.1% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations for Eterna Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eterna Therapeutics Competitors||5021||16445||41406||773||2.60|
As a group, “Pharmaceutical preparations” companies have a potential upside of 75.22%. Given Eterna Therapeutics’ peers higher probable upside, analysts plainly believe Eterna Therapeutics has less favorable growth aspects than its peers.
Volatility and Risk
Eterna Therapeutics has a beta of 4.27, suggesting that its stock price is 327% more volatile than the S&P 500. Comparatively, Eterna Therapeutics’ peers have a beta of 0.95, suggesting that their average stock price is 5% less volatile than the S&P 500.
Eterna Therapeutics peers beat Eterna Therapeutics on 5 of the 9 factors compared.
Eterna Therapeutics Company Profile
Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.